# Emerald Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/emerald-therapeutics

- Industry: Biotechnology
- Headquarters: Menlo Park, US
- Website: www.emeraldtherapeutics.com
- Total disclosed funding: $1.9M
- Latest round: Series B (Jul 1, 2014)
- Investors on record: 2

## About

Emerald Therapeutics is a biotechnology company that offers a remote-controlled life sciences laboratory platform, enabling researchers to conduct experiments efficiently without the limitations of a physical laboratory.Founded in 2010, Emerald Therapeutics is based in Menlo Park, US, and specializes in providing innovative laboratory solutions. The company was co-founded by Brian Frezza and Dj Kleinbaum. In July 2014, Emerald Therapeutics raised USD 1.9 mn in SERIES B funding led by Founders Fund, with participation from Schooner Capital. This round marked its fourth deal since inception, with a total amount raised reaching USD 1.9 mn.Emerald Cloud Lab specializes in providing a remote-controlled life sciences laboratory platform that empowers researchers and organizations to conduct experiments and analyses without the constraints of a physical lab. The company’s primary offering allows users to design, execute, and analyze experiments through a sophisticated web interface that connects them to automated laboratory equipment in a centralized facility. This product is aimed at addressing challenges faced by researchers in various sectors, including pharmaceuticals, biotechnology, and academic institutions, who require high throughput and precision while minimizing operational costs and logistical complexities. Emerald Cloud Lab serves a diverse client base, which includes research institutions, biotech companies, and academic laboratories across North America and Europe, enabling them to accelerate their research and development timelines. The platform was initially launched to provide solutions for remote experiment management, and it has evolved to support a wide range of applications in drug discovery, material science, and synthetic biology.Emerald Cloud Lab generates revenue primarily through a subscription-based model, allowing clients to access its laboratory services and platform features on a recurring basis. This transactional structure includes tiered pricing plans based on the volume of experiments conducted, level of service, or additional features utilized by the clients. Clients typically engage with the company on a B2B basis, establishing partnerships that provide them with the tools necessary for extensive research projects. Additionally, the company offers specific flagship services that may cater to specialized needs within the life sciences sector, enhancing the value provided to its clients. The revenue flow is structured around these subscription agreements, where clients commit to a predetermined volume of experiments or lab time, ensuring steady income for the company while fostering long-term client relationships.In July 2014, Emerald Therapeutics raised USD 1.9 mn in SERIES B funding, which will be utilized to expand its service offerings and enhance its laboratory platform. The company is focused on launching new products designed to improve user experience and broaden its market reach. Additionally, Emerald Therapeutics plans to expand into new geographic markets, specifically targeting regions in Europe and Asia by 2025, to cater to a growing global demand for remote laboratory services.

## Funding rounds

- Series B, Jul 1, 2014, $1.9M — Founders Fund, Schooner Capital

## Investors

- Founders Fund (https://capitalatlas.ai/funds/founders-fund) — Series B
- Schooner Capital (https://capitalatlas.ai/funds/schooner-capital) — Series B